Physicians say last month's Phase III data for Biogen Idec Inc.'s rFVIIIFc could motivate about 15% of hemophilia A patients to switch treatments. Getting to a larger population may have to wait for longer-term data expected late next year.

On Oct. 31, Biogen Idec and partner Swedish Orphan Biovitrum AB reported data from the Phase III A-LONG trial showing that two prophylaxis regimens with rFVIIIFc met the primary endpoint of reducing annualized bleeding rates by 50% or more compared to on-demand treatment.